Evidence map›Paper›PMID 38022629›Full record

ArticleFrontiers in immunology2023

Systematical assessment of the impact of single spike mutations of SARS-CoV-2 Omicron sub-variants on the neutralization capacity of post-vaccination sera.

Maeva Katzmarzyk, Denise Christine Clesle, Joop van den Heuvel, Markus Hoffmann, Henk Garritsen, Stefan Pöhlmann, Henning Jacobsen, Luka Čičin-Šain

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Maeva KatzmarzykDepartment of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Denise Christine ClesleDepartment of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Joop van den HeuvelResearch Group Recombinant Protein Expression, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Markus HoffmannInfection Biology Unit, German Primate Center, Göttingen, Germany.
Henk GarritsenInstitute for Clinical Transfusion Medicine, Klinikum Braunschweig GmbH, Braunschweig, Germany.
Stefan PöhlmannInfection Biology Unit, German Primate Center, Göttingen, Germany.
Henning Jacobsen *Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Luka Čičin-Šain *Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Helmholtz Centre for Infection Research · DEGerman Primate Center · DEKlinikum Braunschweig · DEUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The evolution of novel SARS-CoV-2 variants significantly affects vaccine effectiveness. While these effects can only be studied retrospectively, neutralizing antibody titers are most used as correlates of protection. However, studies assessing neutralizing antibody titers often show heterogeneous data. Methods: To address this, we investigated assay variance and identified virus infection time and dose as factors affecting assay robustness. We next measured neutralization against Omicron sub-variants in cohorts with hybrid or vaccine induced immunity, identifying a gradient of immune escape potential. To evaluate the effect of individual mutations on this immune escape potential of Omicron variants, we systematically assessed the effect of each individual mutation specific to Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5. Results: We cloned a library of pseudo-viruses expressing spikes with single point mutations, and subjected it to pooled sera from vaccinated hosts, thereby identifying multiple mutations that independently affect neutralization potency. Discussion: These data might help to predict antigenic features of novel viral variants carrying these mutations and support the development of broad monoclonal antibodies.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingHumansMutationRetrospective StudiesVaccinationAntibodies, NeutralizingantibodyCOVID-19neutralizing antibodiesomicronSARS-CoV-2spike protein

Identifiers

PMID38022629
PMCPMC10667444
OpenAlexW4388637983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.